Status:
COMPLETED
BDNF Gene Polymorphism and Antidepressants Treatment
Lead Sponsor:
University Hospital, Tours
Collaborating Sponsors:
H. Lundbeck A/S
Conditions:
Depression
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The main hypothesis is that the therapeutic response and pharmacological resistance to ADs in depressed patients can be associated with a polymorphism for the BDNF gene. The research of allelic forms ...
Detailed Description
* The main objective is to research an association between polymorphism for the BDNF gene and the 3-week and 6-week response to a SSRI treatment (escitalopram) in major depression. * A case control pi...
Eligibility Criteria
Inclusion
- Patient suffering a severe depressive episode (according to DSM-IV), evolving since at least 2 weeks before entering the study
- Age superior to 18 years
- Caucasian type
- In absence of any medicinal treatment that could enhance depression: methyldopa, beta-blockers, reserpine,
- In absence of hypothyroidia or anaemia
- Without comorbidity that could affect therapy response : e.g. food disorder, substance abuse or dependence syndrome
Exclusion
- \- Will be excluded from the study the patients for which a modification of the depression diagnosis (according to the DSM-IV criteria) takes place during the period of study
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
188 Patients enrolled
Trial Details
Trial ID
NCT00308893
Start Date
July 1 2006
End Date
June 1 2012
Last Update
December 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CPU CHRU de Tours
Tours, France, 37044